get in touch if you don't see what you're looking for!
We're working on adding all of our packages. Stay tuned or Disease Prioritization Data Package
This package has 16 modules. The Clinical Trials Module has 16 tables. Preview the first five rows of each table or Explore the schema
Clinical Trials Module
16 Tables
Provides detailed information about clinical trials including interventions, trial arms, location, sponsor, trial conditions and more. Information is normalized, linked, and many relevant metadata descriptions are structured and ready for analysis.
id | trial_id | kind | label | description |
---|---|---|---|---|
00002aaa-094e-4fe5-ac0c-e3348e8c506d | NCT06232473 | experimental | Patient Education and Placebo | Participants in this arm will recieve patient education as described above. In addition,
participants will recieve the placebo treatment as described above. |
00005a50-31c6-4a5b-bdd9-5237bc2f8da0 | NCT04699461 | active_comparator | Idelalisib | Participants will be administered 150 mg idelalisib, orally, twice a day throughout each
cycle, where 1 cycle is 4 weeks. |
0000701e-200c-49f2-a6d5-1e15d5488af0 | NCT03151668 | no_intervention | Midazolam | |
0000ac1d-2a1f-4e86-955d-e716eecd6e26 | NCT04485312 | other | chlorhexidine varnish added to the caries preventive protocol | chlorhexidine varnish preventive caries protocol for special needs |
00012472-66b2-4dfc-bb2b-57f3089addf0 | NCT03815305 | active_comparator | Topical CA and Placebo Oral Drug | Patient given 10gr 1% CA ointment and 56 pcs of placebo drug |
Want all 368,994 rows? Let's connect you to sales.
id | trial_id | title | condition_id |
---|---|---|---|
0 | NCT00000726 | Cytomegalovirus Retinitis | 283 |
1 | NCT00000726 | Immunologic Deficiency Syndromes | 28099 |
2 | NCT00000726 | Acquired Immunodeficiency Syndrome | 48294 |
3 | NCT00000726 | Retinitis | 9843 |
4 | NCT00000726 | Communicable Diseases | 28178 |
Want all 343,556 rows? Let's connect you to sales.
id | trial_id | title | drug_id |
---|---|---|---|
0 | NCT00000726 | Foscarnet | 529 |
1 | NCT00000726 | Phosphonoacetic Acid | 2823 |
2 | NCT00000179 | Trazodone | 656 |
3 | NCT00000179 | Haloperidol decanoate | 502 |
4 | NCT00000179 | Haloperidol | 502 |
Want all 307,524 rows? Let's connect you to sales.
trial_id | condition_id |
---|---|
NCT06207370 | 21 |
NCT01306058 | 46 |
NCT00513604 | 48 |
NCT00924001 | 48 |
NCT00301509 | 61 |
Want all 317,187 rows? Let's connect you to sales.
trial_id | country |
---|---|
NCT00000102 | United States |
NCT00000105 | United States |
NCT00000116 | United States |
NCT00000117 | United States |
NCT00000119 | United States |
Want all 359,565 rows? Let's connect you to sales.
id | trial_id | sampling_method | gender | gender_based | gender_description | min_age | max_age | healthy_volunteers | criteria | population |
---|---|---|---|---|---|---|---|---|---|---|
00002007-b79a-468c-8976-5f7df5949f71 | NCT03246529 | All | 0 | 18 Years | 78 Years | No | Inclusion Criteria:
1. Histologically confirmed Multiple Myeloma prior to enrolment and randomization.
2. At least 1 week (7 days) from last induction cycle of combination/multi-agent
cyto-reductive chemotherapy (e.g., KRD [carfilzomib, lenalidomide, dexamethasone] or
VRD (e.g., bortezomib, lenalidomide, dexamethasone) or last single agent
chemotherapy (e.g., lenalidomide, pomalidomide, bortezomib, dexamethasone, etc.)
prior to the first dose of G-CSF for mobilization.
3. Eligible for autologous hematopoietic stem cell transplantation according to the
Investigator's discretion.
4. The subjects should be in first or second CR (including CR and SCR) or PR (including
PR and VGPR).
5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
6. Adequate organ function at screening as defined as below:
1. Hematology:
- White blood cell counts more than 2.5 x 10^9/L
- Absolute neutrophil count more than 1.5 x 10^9/L
2. Platelet count more than 100 x10^9/L Renal Function:
• Glomerular Filtration Rate (GFR) value of ≥15 mL/min/1.732 calculated by
Modification of Diet in Renal Disease (MDRD) equation
3. Hepatic function:
- Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤
2.5 x ULN
- Total Bilirubin ≤ 2.0 x Upper Limit Normal (ULN) unless the subject has
Gilbert disease
4. Coagulation test:
- International Normalized Ratio (INR) or Prothrombin Time (PT): ≤1.5 x ULN
unless subject is receiving anticoagulant therapy, as long as PT or
Partial Thromboplastin Time (PTT) is within therapeutic range of intended
use of anticoagulants
- Activated Partial Thromboplastin Time (aPTT): ≤1.5 x ULN unless subject is
receiving anticoagulant therapy, as long as PT or PTT is within
therapeutic range of intended use of anticoagulants
7. Male subjects must agree to use an adequate method of contraception starting with
the first day of G-CSF administration through 30 days after the last dose of study
drug.
8. Patients must have a signed study informed consent prior to entering the study.
Exclusion Criteria:
1. Previous history of autologous or allogeneic-Hematopoietic Cell Transplantation
(HCT).
2. Failed previous Hematopoietic Stem Cell (HSC) collections or collection attempts.
3. Taken any of the listed below concomitant medications, growth factors or stimulating
agents within the designated washout period:
1. Dexamethasone: 7 days;
2. Thalidomide: 7 days;
3. Lenalidomide: 7 days;
4. Pomalidomide: 7 days;
5. Bortezomib: 7 days;
6. Carfilzomib: 7 days;
7. G-CSF: 14 days;
8. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) or Neulasta®: 21
days;
9. Erythropoietin or erythrocyte stimulating agents: 30 days;
10. Eltrombopag, romiplostim or platelet stimulating agents: 30 days;
11. Carmustine (BCNU): 42 days/6 weeks;
12. Daratumumab: 28 days;
13. Ixazomib: 7 days.
4. Received >6 cycles lifetime exposure to thalidomide or lenalidomide.
5. Received >8 cycles of alkylating agent combinations.
6. Received >6 cycles of melphalan.
7. Received prior treatment with radioimmunotherapy (e.g., radionuclides, holmium).
8. Received prior treatment with venetoclax.
9. Plans to receive maintenance treatment within 60 days post-engraftment (e.g.,
lenalidomide, bortezomib, pomalidomide, thalidomide, carfilzomib, etc.)
10. Has received a live vaccine within 30 days of the planned start of G-CSF
administration. Seasonal flu vaccines that do not contain live virus are permitted.
11. Known active central nervous system (CNS) metastases or carcinomatous meningitis.
12. A history of allergic reactions attributed to compounds of similar chemical or
biologic composition to BL-8040, G-CSF, or other agents used in the study.
13. Has an active infection requiring systemic therapy or uncontrolled infection.
14. Has a known additional malignancy that is progressing or requires active treatment.
15. Has an underlying medical condition that would preclude study participation.
16. Is currently participating and receiving study therapy or has participated in a
study of an investigational agent and received study therapy or used an
investigational device within 4 weeks of the first dose of treatment.
17. O2 saturation < 92% (on room air).
18. Personal history or family history of Long QT Syndrome or Torsade de Pointes.
19. History of unexplained syncope, syncope from an uncorrected cardiac etiology, or
family history of sudden cardiac death.
20. Myocardial infarction, coronary artery bypass grafting (CABG), coronary or cerebral
artery stenting and /or angioplasty, stroke, cardiac surgery, or hospitalization for
congestive heart failure within 3 months or greater than Angina Pectoris Class >2 or
New York Heart Association (NYHA) Heart Failure >2.
21. ECG in screening showing QTcF > 470 msec, and/or PR > 280 msec,.
22. Mobitz II 2nd degree Atrioventricular (AV) Block, 2:1 AV Block, High Grade AV Block,
or Complete Heart Block, unless the patient has an implanted pacemaker or
implantable cardiac defibrillator (ICD) with backup pacing capabilities.
23. Has a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the trial, interfere with the
subject's participation for the full duration of the trial, or is not in the best
interest of the subject to participate, in the opinion of the treating investigator.
24. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
25. Is pregnant or breastfeeding, or expecting to conceive within the projected duration
of the trial, starting with the screening visit through 30 days after the last dose
of study drug.
26. Has a known history of HIV (HIV 1/2 antibodies)
27. Has known active Hepatitis B (e.g., Hepatitis B Surface Antigen [HBsAg] reactive) or
Hepatitis C (e.g., Hepatitis C Virus [HCV] RNA [qualitative] is detected).
28. Untreated or unsuccessfully treated Hepatitis B or C. | |||
00003d89-d1ea-432e-9863-5bcd91e204e4 | NCT01756560 | All | 0 | 18 Years | 75 Years | No | Inclusion Criteria:
- age 18-75, no contraindication to regional anesthesia
Exclusion Criteria:
- peripheral neuropathy | |||
00005b5c-7a71-4602-a7fa-89d453a5decd | NCT00193258 | All | 0 | 18 Years | No | Inclusion Criteria:
To be included in this study, you must meet the following criteria:
- Metastatic or unresectable clear cell renal carcinoma confirmed by biopsy
- Previous nephrectomy is required
- Maximum of 1 previous systemic regimen for metastatic disease.
- Able to perform activities of daily living with minimal assistance
- Measurable disease
- Adequate bone marrow, liver and kidney
- Written informed consent.
Exclusion Criteria:
- Age < 18 years
- Treatment with more than 1 previous systemic regimen
- History of heart attack within 6 months
- Clinically significant cardiovascular disease
- Moderate to severe vascular disease.
- Active brain metastases.
- History or evidence by physical examination of brain tumor
- Seizures not controlled with standard medical therapy
- history of stroke or other serious disorders of the nervous system
- Clinical history of coughing or vomiting blood within the past 3 months.
- PEG tubes or G tubes
- Chronic therapy with NSAIDS or other platelet inhibitors
- Proteinuria
- Nonhealing wound, ulcer, or long bone fracture
- Clinical evidence or history of a bleeding disorder
- Requiring full dose anticoagulation with coumadin
- Receiving chronic steroid therapy
- Significant medical conditions.
- Tumors other than clear cell
- History of stroke within 6 months.
- History of abdominal fistula,perforation,or abscess within 6 months.
Please note: There are additional inclusion/exclusion criteria. The study center will
determine if you meet all of the criteria. If you do not qualify for the trial, study
personnel will explain the reasons. If you do qualify, study personnel will explain the
trial in detail and answer any questions you may have. | ||||
0000a853-07b6-42bf-b37a-74ac0019e8d7 | NCT05443984 | All | 0 | 19 Years | No | - Inclusion Criteria: Subjects must satisfy all the following criteria.
1. Male or female, ≥ 19 years of age at the time of obtaining consent
2. Subjects who had experienced heartburn and regurgitation within 7 days prior to
the screening visit, those whose severity and frequency of symptoms fall under
the following (1) or (2)
⑴ Subjects who have experienced mild or more severe heartburn or regurgitation
at least twice a week
⑵ Subjects who have experienced moderate or more severe heartburn or
regurgitation at least once a week
3. Endoscopically confirmed grade A or higher erosive esophagitis as defined by
†LosAngeles classification within 15 days, prior to randomization
4. Subjects who fully understand this study and voluntarily signed on the informed
consent form
- Exclusion Criteria: Subjects may not satisfy any of the following criteria.
1. Subjects who can't undergo endoscopy
2. Medical History
º Subjects who have warning symptoms of the malignant gastrointestinal tract
such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody
stool. (except negative result for malignancy by endoscopy)
º Subjects with eosinophilic esophagitis (except negative result by esophageal
biopsy)
º Subjects who have esophageal stenosis, gastroesophageal varices, Barrett's
esophagus, active gastric ulcer, gastrointestinal bleeding, or malignant tumor
confirmed by EGD
º Zollinger-Ellison syndrome patients
º Subjects diagnosed with primary esophageal motility disorder, irritable bowel
syndrome (IBS), inflammatory bowel disease (IBD), or suspected with IBS in the
last 3 months and with a current history of the disease including pancreatitis
º Subjects who have a history of gastric acid suppression surgery,
gastrointestinal or esophageal surgery (except appendectomy, cholecystectomy,
polypectomy)
º Subjects with a history of clinically significant hepatic, renal,
cardiovascular, respiratory, endocrine, urinary, neuro-psychiatric,
hemato-oncologic disorder
º Subjects who have a history of malignant tumor in 5 years at the time of
screening. However, excluding subjects with malignant gastrointestinal cancer
regardless of the period.
3. Laboratory Test
Screening laboratory test showing any of the following abnormal laboratory
results:
º ALT or AST > 2.0 x ULN
º ALP or GGT > 2.0 x ULN
º Total bilirubin > 2.0 x ULN
º eGFR<70 mL/min/1.73 m2 (CKD-EPI formula)
º Positive result for Serological test (HBsAg, HCV Ab, HIV Ab, Syphilis reagin
test)
º Clinically significant ECG abnormalities
4. Allergy and drug hypersensitivity
º Known hypersensitivity to the active ingredient or excipients of the
investigational product
º Clinically significant allergies (except mild allergic rhinitis) or
hypersensitivity history to drugs. (Aspirin, antibiotics, etc.)
5. Prohibited medication and therapy
º Subjects who take gastric acid suppressant like P-CAB, PPI within 2weeks
prior to EGD of screening procedure
º Subjects who take medication (antacids, prokinetics, H2RA, etc.) related to
reflux esophagitis more than 2times within 1week prior to EGD of screening
procedure
º Subjects who need to take medication (aspirin, NSAIDs, etc.) that may cause
an ulcer, during the study period
º Subjects who are on or need to be on the medications which categorized as
contraindicated in this clinical trial.
However, subjects who are on the contraindicated medications can participate in
the trial after the washout period of 2 weeks. If five times of the half-life
of the contraindicated medications exceeds 2 weeks, the washout period will be
set as five times of the half-life.
6. Pregnant and lactating women
7. Contraception Subjects who do not agree to use medically acceptable methods of
contraception during the period study
8. Subjects with clinically significant psychiatric disorder and a history with a
drug and alcohol abuse.
9. Subjects who are judged unsuitable to participate in the study in the opinion
of the investigator | ||||
00012e02-17e3-4bd5-95bc-ce17b49e8423 | NCT04163419 | All | 0 | 18 Years | No | Inclusion Criteria:
1. Patients must have a confirmed diagnosis schwannomatosis by fulfilling either
clinical or molecular diagnosis.
2. Age ≥ 18 years. Patients < 18 years are excluded since the safety profile of
tanezumab in this population has not been determined.
3. ECOG performance status ≤2 or Karnofsky ≥60%
4. Participants must have normal organ and marrow function as defined per the full
protocol
5. The subject's weight must be≥ 45 kg at Screening.
6. The subject must be willing to avoid prohibited pain medications (including
non-steroidal anti-inflammatory drugs) throughout the duration of the study except
as permitted per Protocol.
7. Subject must have moderate to severe pain secondary to schwannomatosis, defined as
Score ≥5 on the Numeric Rating Scale-11 (NRS-11) at Screening.
8. Subject must have failure, intolerance, or contraindication to at least three
standard of care therapies:
- Documented history indicating that NSAID therapy has not provided adequate pain
relief or subject is unable to take NSAIDs due to contraindication or inability
to tolerate.
- Documented history indicating that opioid treatment has not provided adequate
pain relief or subject is unwilling to take opioids, or unable to take opioids
due to contraindication or inability to tolerate
- Documented history indicating that neuropathic pain medications, such as
gabapentin, pregabalin, or others, have not provided adequate pain relief or
subject is unable to take these treatments due to contraindication or inability
to tolerate.
9. Female subjects of childbearing potential and at risk for pregnancy (e.g., not
abstinent) must agree to use 2 highly effective methods of contraception throughout
the study and for 112 days (16 weeks) after the last dose of assigned subcutaneous
study medication.
Exclusion Criteria:
1. Subjects with any of the following criteria: evidence of bilateral vestibular
schwannomas on imaging, a known germline pathogenic NF2 mutation, a first-degree
relative who meets diagnostic criteria for NF2, or have schwannomas limited to a
previous radiation field.
2. Subjects with intracranial meningioma associated with cerebral edema on
neuroimaging. Note: presence of intracranial meningioma itself is not an exclusion
criterion.
3. Subjects who have had surgery, chemotherapy or radiotherapy within 4 weeks (6 weeks
for nitrosoureas or mitomycin C) for treatment of a painful schwannomatosis-related
tumor prior to entering the study or those who have not recovered from adverse
events due to agents administered more than 4 weeks earlier.
4. Participation in other studies involving investigational drug(s) (Phases 1-4) within
30 days (or 90 days for biologics) before Screening and/or during study
participation.
5. Subjects receiving anticoagulation to treat an underlying medical condition.
6. Subject has a history of allergic or anaphylactic reaction to a therapeutic or
diagnostic monoclonal antibody or IgG fusion protein.
7. The subject's pain is related to a non-schwannomatosis cause such as prior cancer
therapy, infection, bowel obstruction/perforation, spinal cord compression, or
fracture or impending fracture of weight bearing bone.
8. The subject has a diagnosis of malignancy in the last 3 years (except for Gleason 6
prostate cancer, basal cell carcinoma or carcinoma in situ).
9. Use of concurrent adjuvant analgesics such as serotonin norepinephrine reuptake
inhibitors (SNRI), tricyclic antidepressants, anticonvulsant medication, or muscle
relaxants (unless the drugs were started at least 30 days prior to Screening and are
maintained at a stable dose).
10. Use of concurrent analgesic non-steroidal anti-inflammatory drugs (NSAIDs, including
selective COX-2 inhibitors) unless the subject is expected to be able to discontinue
these medications at least 2 weeks prior to treatment. Note: Subjects who take daily
low dose aspirin (≤ 325 mg as per local prescribing practice) therapy for
cardiovascular prophylaxis are not excluded from participation.
11. Diagnosis of osteoarthritis of the knee or hip as defined by the American College of
Rheumatology (ACR) combined clinical and radiographic criteria; Radiographic
criteria will be assessed by the Central Reader.
12. Use of concurrent corticosteroids (except for inhaled or topical corticosteroids as
needed for management of ongoing pulmonary or dermatologic conditions)
13. Subjects considered unfit for surgery, defined as Grade >3 on the American Society
of Anesthesiologists (ASA) physical classification system for surgery or subjects
who would not be willing to undergo joint replacement surgery if required.
14. Subjects with symptoms and radiographic findings (i.e. joint space narrowing,
osteophytes) consistent with osteoarthritis in the shoulder.
15. History of significant trauma or surgery to a major joint (e.g. hip, knee or
shoulder) within one year prior to Screening.
16. A history of osteonecrosis or osteoporotic fracture (i.e., a subject with a history
of osteoporosis and a minimally traumatic or atraumatic fracture).
17. Radiographic (x-ray) evidence of any of the following conditions as determined by
the central radiology reviewer at Screening: 1) rapidly progressive osteoarthritis,
2) atrophic or hypotrophic osteoarthritis, 3) subchondral insufficiency fracture, 4)
spontaneous osteonecrosis of the knee (SPONK), 5) osteonecrosis, or 6) pathologic
fracture.
18. Subjects who have evidence of orthostatic hypotension based upon replicate
orthostatic blood pressure measurements at Screening.
19. Subjects with a total impact score of >7 on the Survey of Autonomic Symptoms (SAS)
at Screening.
20. Diagnosis of a transient ischemic attack in the 6 months prior to Screening or
diagnosis of stroke with residual deficits (e.g., aphasia, substantial motor or
sensory deficits), that would preclude completion of required study activities.
21. History, diagnosis, or signs and symptoms of clinically significant neurological
22. Subjects with a past history of carpal tunnel syndrome (CTS) with signs or symptoms
of CTS in the one year prior to Screening.
23. Subject with a history of significant alcohol, analgesic, or narcotic substance
abuse within the six months prior to Screening.
24. Subject who, in the judgement of the investigator, is expected to require a surgical
procedure during the duration of the study.
25. Previous exposure to exogenous nerve growth factor or to an anti-nerve growth factor
antibody.
26. Subjects who are investigational site staff members directly involved in the conduct
of the trial and their family members, site staff members otherwise supervised by
the Investigator, or subjects who are Pfizer employees directly involved in the
conduct of the trial
27. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance
with study requirements.
28. Pregnant females; breastfeeding females; females of childbearing potential not using
two (2) methods of highly effective contraception or not agreeing to continue two
(2) methods of highly effective contraception for 112 days (16 weeks) after last
dose of investigational product.
29. Any subject who, in the judgement of the investigator, is deemed inappropriate for
participation in the study. |
Want all 185,145 rows? Let's connect you to sales.
id | trial_id | identifier | kind |
---|---|---|---|
0 | NCT00000726 | NCT00000726 | primary |
1 | NCT00000726 | ACTG 015 | org_study_id |
2 | NCT00000726 | FDA 20D | external |
3 | NCT00000726 | 10991 | external |
4 | NCT00001302 | NCT00001302 | primary |
Want all 465,158 rows? Let's connect you to sales.
intervention_id | arm_group_id |
---|---|
00001893-473d-4d35-b0d6-019d54c53460 | d177da34-5f45-4231-914e-a81b486a64f2 |
00003aab-b2ea-43dc-b89d-ac18b3901e92 | 5b79b5d8-68c8-42e1-8ac9-6e98964b75ba |
00004f13-b15b-49c7-b4b2-fbdd9d414d52 | 2d3be8b8-26c6-4732-bd87-1a5495d1fde0 |
00004f13-b15b-49c7-b4b2-fbdd9d414d52 | 3852a4f1-ee82-4717-9674-24b885150288 |
00004f13-b15b-49c7-b4b2-fbdd9d414d52 | 45ef5f15-0334-4179-94d4-6e78b5ab1b8c |
Want all 565,768 rows? Let's connect you to sales.
id | trial_id | kind | title | description |
---|---|---|---|---|
00001893-473d-4d35-b0d6-019d54c53460 | NCT02992015 | drug | Gemcitabine | Participants receive a one time IV dose of gemcitabine prior to having standard of care
surgery. |
00003aab-b2ea-43dc-b89d-ac18b3901e92 | NCT05605899 | biological | Axicabtagene Ciloleucel | A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells |
00004f13-b15b-49c7-b4b2-fbdd9d414d52 | NCT03055936 | drug | Carbidopa | Carbidopa 12.5 mg or 25 mg or 65 mg |
00007903-41bc-4943-9299-e78ae1330a1b | NCT02424305 | drug | LEO 43204 gel 0.018% | |
00007a6a-0c46-446e-b660-d7a5078d4125 | NCT00124748 | drug | Imatinib mesylate | Imatinib is packaged in bottles as 100mg and 400mg tablets |
Want all 423,583 rows? Let's connect you to sales.
id | intervention_id | drug_id |
---|---|---|
223653 | 00001893-473d-4d35-b0d6-019d54c53460 | 441 |
336188 | 00003aab-b2ea-43dc-b89d-ac18b3901e92 | 14009 |
227729 | 00004f13-b15b-49c7-b4b2-fbdd9d414d52 | 190 |
192356 | 00007903-41bc-4943-9299-e78ae1330a1b | 16027 |
21518 | 00007a6a-0c46-446e-b660-d7a5078d4125 | 619 |
Want all 373,446 rows? Let's connect you to sales.
id | intervention_id | name |
---|---|---|
0 | 2e37e858-4b10-4024-a1d3-6b098eb85d42 | Elavil |
1 | 1bcac8d4-8e28-40f9-8823-542aeaa25058 | elavil plus prozac |
2 | 7045ffaa-6662-4c28-8337-343637f3b492 | Subutex |
3 | 7045ffaa-6662-4c28-8337-343637f3b492 | Suboxone |
4 | 2af7f79e-5717-4256-9fbe-4b65ea809832 | Zoloft |
Want all 343,216 rows? Let's connect you to sales.
id | intervention_id | product_id |
---|---|---|
70275 | 00001893-473d-4d35-b0d6-019d54c53460 | 477726 |
99499 | 00003aab-b2ea-43dc-b89d-ac18b3901e92 | 387170 |
4277 | 00007a6a-0c46-446e-b660-d7a5078d4125 | 91793 |
4276 | 00007a6a-0c46-446e-b660-d7a5078d4125 | 140871 |
33463 | 00036210-302a-4295-9ba4-cabad6029b49 | 107929 |
Want all 106,032 rows? Let's connect you to sales.
trial_id | phase |
---|---|
NCT00017381 | 0 |
NCT00091286 | 0 |
NCT00140556 | 0 |
NCT00176059 | 0 |
NCT00187941 | 0 |
Want all 167,171 rows? Let's connect you to sales.
id | trial_id | company_id | title | normalized_title | agency_class | lead_sponsor |
---|---|---|---|---|---|---|
0 | NCT00000726 | National Institute of Allergy and Infectious Diseases (NIAID) | nih | 1 | ||
1 | NCT00001302 | National Cancer Institute (NCI) | nih | 1 | ||
2 | NCT00000179 | National Institute on Aging (NIA) | nih | 1 | ||
3 | NCT00000333 | Washington D.C. Veterans Affairs Medical Center | us_fed | 0 | ||
4 | NCT00000333 | National Institute on Drug Abuse (NIDA) | nih | 1 |
Want all 285,042 rows? Let's connect you to sales.
identifier | title | official_title | status | purpose | acronym | summary | description | expanded_access | why_stopped | why_stopped_category_id | start_date | end_date | end_date_kind |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT00000102 | Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets | completed | treatment | This study will test the ability of extended release nifedipine (Procardia XL), a blood
pressure medication, to permit a decrease in the dose of glucocorticoid medication
children take to treat congenital adrenal hyperplasia (CAH). | This protocol is designed to assess both acute and chronic effects of the calcium channel
antagonist, nifedipine, on the hypothalamic-pituitary-adrenal axis in patients with
congenital adrenal hyperplasia. The multicenter trial is composed of two phases and will
involve a double-blind, placebo-controlled parallel design. The goal of Phase I is to
examine the ability of nifedipine vs. placebo to decrease adrenocorticotropic hormone
(ACTH) levels, as well as to begin to assess the dose-dependency of nifedipine effects.
The goal of Phase II is to evaluate the long-term effects of nifedipine; that is, can
attenuation of ACTH release by nifedipine permit a decrease in the dosage of
glucocorticoid needed to suppress the HPA axis? Such a decrease would, in turn, reduce
the deleterious effects of glucocorticoid treatment in CAH. | 1 | |||||||
NCT00000105 | Vaccination With Tetanus and KLH to Assess Immune Responses. | Vaccination With Tetanus Toxoid and Keyhole Limpet Hemocyanin (KLH) to Assess Antigen-Specific Immune Responses | terminated | The purpose of this study is to learn how the immune system works in response to
vaccines. We will give the vaccines to subjects who have cancer but have not had
treatment, and to patients who have had chemotherapy or stem cell transplant. Some
patients will get vaccines while they are on treatments which boost the immune system
(like the immune stimulating drug interleukin-2 or IL-2). Although we have safely treated
many patients with immune boosting drugs, we do not yet know if they improve the body's
immune system to respond better to a vaccine. Some healthy volunteers will also be given
the vaccines in order to serve as control subjects to get a good measure of the normal
immune response. We will compare the patients and the healthy volunteers to study how
their immune systems respond to the vaccines.
There are several different types of white cells in the blood. We are interested in
immune cells in the blood called T-cells. These T-cells detect foreign substances in the
body (like viruses and cancer cells). We are trying to learn more about how the body
fights these foreign substances. Our goal is to develop cancer vaccines which would teach
T-cells to detect and kill cancer cells better. We know that in healthy people the immune
system effectively protects against recurrent virus infection. For example, that is why
people only get "mono" (mononucleosis) once under normal circumstances. When the body is
infected with the "mono" virus, the immune system remembers and prevents further
infection. We are trying to use the immune system to prevent cancer relapse. To test
this, we will give two vaccines which have been used to measure these immune responses.
Blood samples will be studied from cancer patients and will be compared to similar
samples from normal subjects. | Patients will receive each vaccine once only consisting of:
Arm A: Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml
intramuscularly (this arm closed 1/2/02).
Arm B: Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml
intramuscularly (this arm closed 3/18/03).
Arm C: Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (now replaced with vegetable (VG)
source after 8/31/06 to increase product safety) subcutaneous Tetanus toxoid 0.5 ml
intramuscularly (this arm open 3/18/03).
Subjects ineligible for tetanus may still receive KLH on this protocol. This is
especially true given the national shortage of tetanus vaccines. Subjects will be
eligible for tetanus when it becomes available if there has been no significant change in
treatment interventions or overall health status and it is within 3 months of the KLH
vaccine. | 1 | Replaced by another study. | 136 | 2002-07-01 | 2012-03-01 | actual | ||
NCT00000114 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | completed | treatment | To determine whether supplements of vitamin A or vitamin E alone or in combination affect
the course of retinitis pigmentosa. | Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide
prevalence of about 1 in 4,000. Patients typically report night blindness in adolescence
and lose vision in the midperipheral followed by far-peripheral visual field in adulthood
due to progressive loss of both rod and cone function. Most patients have reductions in
central vision by age 50 to 80 years. Modern-day electroretinograms (ERGs) make it
possible to record retinal responses from most patients with remaining vision and thereby
monitor objectively the course of their disease.
While the natural course of retinal degeneration in the common forms of RP was being
studied, it was noted that a subgroup of patients aged 18 through 49 who were treating
themselves with both vitamin A and vitamin E and other nutritional supplements exhibited
less decline in ERG amplitude over a 2-year period. These preliminary findings, as well
as the known roles of vitamins A and E in maintaining normal photoreceptor function and
structure, prompted this randomized, controlled trial to determine whether these vitamins
alone or in combination would halt or slow the progression of the common forms of RP.
This study was a randomized, controlled double-masked trial with 2 x 2 factorial design
and duration of 4 to 6 years. Patients were assigned to one of four treatment groups:
15,000 IU/day vitamin A
15,000 IU/day vitamin A + 400 IU/day vitamin E
trace amounts of both vitamins A and E
400 IU/day of vitamin E
The main outcome measure was the 30-Hz cone ERG amplitude. In addition, visual field and
visual acuity were measured annually. | 1 | 1984-05-01 | 1987-06-01 | actual | ||||
NCT00000115 | Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema | completed | treatment | To test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid
macular edema. | Uveitis, an intraocular inflammatory disease, is the cause of about 10 percent of visual
impairment in the United States. Uveitis may lead to many sight-threatening conditions,
including cataract, vitreal opacities, glaucoma, and, most commonly, cystoid macular
edema. Reduction of swelling or edema within the retina depends on the movement of fluid
from the retina through the choroid. A number of studies indicate that this process
requires active transport of fluid ions by the retinal pigment epithelium and may involve
the carbonic anhydrase system. Current treatment of uveitis-associated cystoid macular
edema requires the use of immunosuppressive or anti-inflammatory agents. However, many
patients are either resistant or intolerant to this therapy. Recent reports suggested
that acetazolamide, a carbonic anhydrase inhibitor that is used to lower intraocular
pressure in some glaucoma patients, might be safe and effective in reducing
uveitis-associated cystoid macular edema.
Because the course of ocular inflammatory disease can be variable, a double-masked,
randomized, crossover trial was designed to test the efficacy of acetazolamide compared
with a placebo for the treatment of uveitis-associated cystoid macular edema. Randomized
adult patients received either oral acetazolamide sodium 500 mg or a matched placebo
every 12 hours for the first 4 weeks of the study. Children 8 years of age or older
received a lesser dose based on body weight. Following a 4-week period, during which no
medication was given, patients then received a 4-week course of the opposite medication.
Primary end points included reduction in cystoid macular edema (graded on fluorescein
angiography) and improvement in visual acuity (measured on standardized Early Treatment
Diabetic Retinopathy Study [ETDRS] charts). Laser acuity was also assessed as a secondary
outcome variable. Adverse effects of the acetazolamide therapy were monitored by clinical
and laboratory examinations.
A total of 40 patients were recruited for the study. Patients were seen at the beginning
of the study for baseline measurements and at 4, 8, and 12 weeks after enrollment into
the study. | 1 | 1990-12-01 | 1994-06-01 | actual | ||||
NCT00000116 | Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A | Clinical Trial of Docosahexaenoic Acid (DHA) in Patients With Retinitis Pigmentosa Receiving Vitamin A Treatment | completed | treatment | The purpose of this trial is to determine whether a nutritional supplement in addition to
vitamin A will slow the course of retinitis pigmentosa. | Retinitis pigmentosa (RP) is a group of inherited retinal degenerations with a worldwide
prevalence of approximately 1 in 4,000. Patients typically report night blindness and
difficulty with midperipheral visual field in adolescence. As the condition progresses,
they lose far peripheral visual field. Most patients have reductions in central vision by
age 50 to 80 years. Based on electroretinograms (ERGs), the course of the disease can be
slowed on average among adults on 15,000 IU/day of vitamin A palmitate. While conducting
the trial on the effects of vitamin A on RP, it became apparent that another substance in
the diet could be affecting the course of the disease. This prompted the present
randomized, controlled trial.
This study is a randomized, controlled, double-masked trial with a planned duration of 5
years. Patients with the common forms of RP are assigned to either a test or a control
group. All receive 15,000 IU/day of vitamin A palmitate in addition to either 1200 mg/d
of docosahexaenoic acid or control capsules. Participants will not know the contents of
the supplement or the group to which they have been assigned until the end of the trial.
The main outcome measurement is the total point score on the Humphrey Field Analyzer
(HFA). In addition, computer-averaged 30-Hz cone ERG amplitudes and visual acuity are
measured annually. | 1 | 1996-05-01 | 2002-09-01 | actual |
Want all 185,509 rows? Let's connect you to sales.
id | category | definition | safety_efficacy_concern |
---|---|---|---|
1 | Business Decision | The trial has been terminated due to strategic decisions, administrative reasons, sponsor, or company decision. | 0 |
6 | Change in Medical/Clinical Practices | The drug(s) of interest might not be suitable to the disease that they were trying to treat due to changes in medical or clinical practices.
1. Surgeons stopped doing procedures
2. Additional published information on the topic since starting the study
3. Study no longer consistent with current clinical practice
| 0 |
11 | Competing Studies | The study drug(s) are having worse/futile results in similar competing trials. | 0 |
16 | Completed | Trial was successfully completed (user input was incorrectly marked as terminated). [eg. accrual was reached] | 0 |
21 | Conflict of Interest | The parties involved had conflicts of interests. | 0 |
Want all 30 rows? Let's connect you to sales.
Showing 16 of 16 tables